AssureCKD Featured by University of Manitoba for Breakthrough Kidney Screening Innovation
AssureCKD has been featured by the University of Manitoba (UM) in a recent UM Today article highlighting the company’s university-backed innovation aimed at enabling earlier diagnosis of chronic kidney disease (CKD).
The article, “Innovation Success: UM-backed tech promises early diagnosis of chronic kidney disease,” showcases AssureCKD’s MATLOC lab-on-a-chip platform, a point-of-care kidney screening technology developed through more than a decade of research collaboration with UM investigators.
A UM-Backed Innovation with Global Impact Potential
UM Today highlights how AssureCKD emerged from UM-led research spearheaded by Dr. Claudio Rigatto (Rady Faculty of Health Sciences) and Dr. Francis Lin (Faculty of Science; Rady Faculty of Health Sciences). The MATLOC platform integrates microfluidics and immunoassay science to deliver accurate kidney screening in a compact, affordable format designed for use beyond traditional laboratories.
Chronic kidney disease affects close to one billion people globally and nearly one in ten Canadians, yet diagnosis often occurs late due to the cost and limited accessibility of lab-based testing. MATLOC aims to address this gap by enabling screening at the point of care, including clinics, community settings, and underserved regions.
Recognition of Research-to-Impact Collaboration
The UM Today feature underscores the strength of the collaboration between AssureCKD and the University of Manitoba, from early-stage research through translational development. UM’s support has played a key role in enabling interdisciplinary collaboration, training research personnel, and accelerating progress toward real-world clinical applications.
The article also references recent federal funding supporting continued development of AssureCKD’s easy-to-use test kits, reinforcing the momentum behind the technology’s path toward clinical deployment.
Advancing Toward Clinical and Regulatory Milestones
As highlighted by UM Today, the MATLOC platform is now advancing toward regulatory clearance in Canada and the United States, positioning AssureCKD for future clinical and commercial rollout. Recent peer-reviewed publications from the UM–AssureCKD research team further validate the scientific foundation of the technology and its potential role in preventive kidney care.
External Recognition of AssureCKD’s Mission
Being featured by the University of Manitoba reflects AssureCKD’s commitment to translating academic research into impactful healthcare solutions. The recognition reinforces the company’s mission to shift kidney care toward earlier detection, prevention, and improved health equity.
